We are live on ! Find out more

Moleculin Biotech

MBRX

Market cap $11M

0.5669 USD

+0.0390

7.39%

At close Updated Sep 24, 4:00 PM EDT

Pre-market

After hours

0.5545

-0.0124

2.19%

1 day

7.39%

5 days

-27.35%

1 month

-6.96%

3 months

-80.65%

6 months

-74.8%

Year to date

-84.34%

1 year

-94.67%

5 years

-99.95%

10 years

-100%

About: Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Employees: 17

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 9.1%

Neutral 81.8%

Negative 9.1%

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

- Video webcast now available here

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

Zacks Investment Research

Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframe MIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selection Cash position, including $9.3 million raised after quarter-end, expected to fund operations into the first quarter of 2027 Absence of cardiotoxicity continues in the MIRACLE trial HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the second quarter ended June 30, 2026, and highlighted continued progress in its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML). Moleculin continues to advance the pivotal Phase 2/3 MIRACLE trial following positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A, which showed complete remission rates at least three times greater than the control arm.

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Moleculin Announces Pricing of $9.3 Million Public Offering

HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the “Common Warrants”) to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants. The Common Warrants will be immediately exercisable at an exercise price of $0.75 per share and will expire five years following the initial exercise date. The offering is expected to close on or about August 3, 2026, subject to satisfaction of customary closing conditions.

Moleculin Announces Pricing of $9.3 Million Public Offering

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment.

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

Why is Moleculin Stock Falling Today?

Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did not reach statistical significance.

Why is Moleculin Stock Falling Today?

See News Rankings

Price charts implemented using Lightweight Charts™